Pulse Technologies’ HSR™ electrode surface treatment is now part of Cardionomic’s Cardiac Pulmonary Nerve Stimulation (CPNS) system for the treatment of heart failure.
QUAKERTOWN, Pa., May 16, 2022 /PRNewswire/ — Pulse Technologies Inc. announced that its proprietary Hierarchical Surface Restructuring (HSR™) technology is being used as part of Cardionomic’s Cardiac Pulmonary Nerve Stimulation (CPNS) System for the treatment of patients with acute decompensated heart failure (ADHF).
Mentioned Steve GoedekeCardionomic CEO, “Hierarchical surface restructuring is an enabling technology for Cardionomic as we develop our novel therapy to treat acute decompensated heart failure.”
Revolutionary patented HSR™ technology modifies the surface of implantable electrodes and microelectrode arrays. The process enables an engineered surface that not only meets customers’ precise performance requirements, but can also improve charge storage capacity, increase capacity and reduce impedance. HSR™ technology eliminates the risk of delamination, cracking and peeling associated with surface coatings, resulting in unparalleled durability. These improvements may enable smaller devices that have lower hardware costs and provide patient benefits.